Prognostic factors in patients treated with transarterial radioembolization for unresectable and chemorefractory colorectal cancer with liver metastases

References

• Dutton SJ, Kenealy N, Love SB, et al. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer. 2014;14:497.
   PubMed Web of Science ®Google Scholar
• Mattar RE, Al-Alem F, Simoneau E, et al. Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection. World J Gastroenterol. 2016;22(2):567–581.
   PubMed Web of Science ®Google Scholar
• Alberts SR, Poston GJ. Treatment advances in liver-limited metastatic colorectal cancer. Clin Colorectal Cancer. 2011;10(4):258–265.
   PubMed Web of Science ®Google Scholar
• Yu JI, Park HC, Choi DH, et al. Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer. Radiat Oncol J. 2016;34(1):34–44.
   PubMed Web of Science ®Google Scholar
• Golfieri R, Mosconi C, Giampalma E, et al. Selective transarterial radioembolisation of unresectable liver-dominant colorectal cancer refractory to chemotherapy. Radiol Med. 2015;120(8):767–776.
   PubMed Web of Science ®Google Scholar
• Jia Z, Paz-Fumagalli R, Frey G, et al. Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results. J Cancer Res Clin Oncol. 2017;143(3):481–489.
   PubMed Web of Science ®Google Scholar
• Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations [erratum in J Vasc Interv Radiol. 2006;17(10):1594]. J Vasc Interv Radiol. 2006;17(8):1251–1278.
   PubMed Web of Science ®Google Scholar
• Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68(1):13–23.
   PubMed Web of Science ®Google Scholar
• Salem R, Lewandowski RJ, Sato KT, et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol. 2007;10(1):12–29.
   PubMedGoogle Scholar
• Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics. 2005;25(Suppl 1):s41–55.
   PubMedGoogle Scholar
• Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31(3):271–279.
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312.
   PubMed Web of Science ®Google Scholar
• Altomare I, Bendell JC, Bullock KE, et al. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist. 2011;16(8):1131–1137.
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006;24(30):4914–4921.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Rosen LS, Marshall JL, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007;25(30):4793–4799.
   PubMed Web of Science ®Google Scholar
• Evans KA, Richardson MG, Pavlakis N, et al. Survival outcomes of a salvage patient population after radioembolization of hepatic metastases with yttrium-90 microspheres. J Vasc Interv Radiol. 2010;21(10):1521–1526.
   PubMed Web of Science ®Google Scholar
• Bester L, Meteling B, Pocock N, et al. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol. 2012;23(1):96–105.
   PubMed Web of Science ®Google Scholar
• Jakobs TF, Paprottka KJ, Raeßler F, et al. Robust evidence for long-term survival with 90Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer. Eur Radiol. 2017;27(1):113–119.
   PubMed Web of Science ®Google Scholar
• Cosimelli M, Golfieri R, Cagol PP, et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer. 2010;103(3):324–331.
   PubMed Web of Science ®Google Scholar
• Nace GW, Steel JL, Amesur N, et al. Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int J Surg Oncol. 2011;2011:571261.
   PubMedGoogle Scholar
• Saxena A, Meteling B, Kapoor J, et al. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients. Ann Surg Oncol. 2015;22(3):794–802.
   PubMed Web of Science ®Google Scholar
• Weiner AA, Gui B, Newman NB, et al. Predictors of Survival after Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases. J Vasc Interv Radiol. 2018;29(8):1094–1100.
   PubMed Web of Science ®Google Scholar
• Faron A, Pieper CC, Schmeel FC, et al. Fat-free muscle area measured by magnetic resonance imaging predicts overall survival of patients undergoing radioembolization of colorectal cancer liver metastases. Eur Radiol. 2019 Jan 28. DOI:10.1007/s00330-018-5976-z.
   PubMed Web of Science ®Google Scholar
• Lahti SJ, Xing M, Zhang D, et al. KRAS status as an independent prognostic factor for survival after Yttrium-90 Radioembolization therapy for unresectable colorectal cancer liver metastases. J Vasc Interv Radiol. 2015;26(8):1102–1111.
   PubMed Web of Science ®Google Scholar
• Fowler JF, Tomé WA, Fenwick JD, et al. A challenge to traditional radiation oncology [errata in Int J Radiat Oncol Biol Phys. 2005;61(3):962 and Int J Radiat Oncol Biol Phys. 2013;87(2):233]. Int J Radiat Oncol Biol Phys. 2004;60(4):1241–1256.
   PubMed Web of Science ®Google Scholar
• Garin E, Rolland Y, Pracht M, et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90 Y-loaded glass microsphere radioembolization. Liver Int. 2017;37(1):101–110.
   PubMed Web of Science ®Google Scholar
• Tampellini M, Ottone A, Alabiso I, et al. The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy. Tumour Biol. 2015;36(3):1519–1527.
   PubMedGoogle Scholar
• Uysal M, Bozcuk H, Sezgin Göksu S, et al. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab. Biomed Pharmacother. 2014;68(4):409–412.
   PubMed Web of Science ®Google Scholar
• John SK, Robinson SM, Rehman S, et al. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study. Dig Surg. 2013;30(4–6):293–301.
   PubMed Web of Science ®Google Scholar